Related Experiment Video
Updated: Jun 16, 2026
05:31
A Fluorescent Screening Assay for Identifying Modulators of GIRK Channels
Published on: April 24, 2012
Pituitary somatostatin receptor signaling
Anat Ben-Shlomo1, Shlomo Melmed
1Pituitary Center, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048, USA.
Trends in Endocrinology and Metabolism: TEM
|February 13, 2010
Summary
Somatotropin-release inhibitory factor (SRIF) regulates pituitary function. Understanding its receptor signaling in the pituitary is key for developing new treatments for pituitary disorders.
Area of Science:
- Endocrinology
- Molecular Biology
- Neuroscience
Background:
- Somatotropin-release inhibitory factor (SRIF) is a key regulator of pituitary hormone secretion and cell growth.
- Five SRIF receptor subtypes (SSTR1-5) are G-protein coupled receptors, with SSTR2 and SSTR5 predominantly expressed in the pituitary.
- New SRIF analogs are emerging for pituitary disease treatment.
Purpose of the Study:
- To evaluate current knowledge of cell-specific pituitary SRIF receptor signaling.
- To identify areas for future research in pituitary SRIF receptor mechanisms.
- To inform therapeutic development for pituitary disorders.
Main Methods:
- Literature review of cell-specific pituitary SRIF receptor signaling.
- Analysis of existing data on SSTR expression and function in the pituitary.
- Identification of knowledge gaps and future research directions.
Main Results:
- SRIF predominantly inhibits pituitary hormone secretion and, to a lesser extent, cell growth.
- SSTR2 and SSTR5 are the primary SRIF receptor subtypes in the pituitary.
- Specific cell-type signaling pathways for pituitary SRIF receptors are not fully elucidated.
Conclusions:
- Comprehensive understanding of pituitary SRIF receptor signaling is crucial for advancing therapeutic strategies.
- Further research into cell-specific signaling is needed to fully leverage SRIF analogs for pituitary disease treatment.
- Elucidating these mechanisms will enhance understanding of pituitary function and inform drug development.
More Related Videos
08:55A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
06:54Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
Related Concept Videos
01:28Insulin: The Receptor and Signaling Pathways
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
01:16TGF - β Signaling Pathway
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:22Amplifying Signals via Enzymatic Cascade
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...